Danaher Corporation Fourth Quarter 2025 Earnings Release January 28, 2026 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those ...

Core Viewpoint - Danaher Corp's annual profit forecast aligns closely with Wall Street estimates, and the company exceeded fourth-quarter profit and revenue expectations due to improving conditions in the life sciences sector [1] Group 1: Financial Performance - Danaher reported fourth-quarter profit and revenue that surpassed market expectations, indicating strong operational performance [1] - The company's annual profit forecast is largely in line with analysts' predictions, suggesting stability in future earnings [1] Group 2: Market Conditions - Improving conditions in the life sciences sector have positively impacted Danaher's performance, reflecting broader trends in the industry [1]

(GAAP)**|**20.40%**||**24.90%**||**12.00%**||**26.80%**||Full year 2025 impact from operating profit margins ofbusinesses that have been owned for less than one yearor were disposed of during such period and did notqualify as discontinued operations|(0.20)||—||(0.30)||(0.15)||Full year 2025 resolution of an acquisition contingency inthe Diagnostics segment|0.05||—||—||0.10||Full year 2025 impairment charges related to tradenames in the Life Sciences and Diagnostics segmentsand technology, other intangible a ...

Microsoft Corporation (NASDAQ:MSFT) is one of the stocks in focus as Jim Cramer shared his weekly game plan. Cramer highlighted why the company’s valuation has dropped. He stated: CNBC Investing Club members, look out. You’re going to be flooded with emails Wednesday because Charitable Trust holdings, Danaher, Starbucks, GE Vernova, Microsoft, Meta, and Corning all report. Let me give you a preview… A bunch of the Mag Seven stocks have been underperforming, at least until today, when they roared. Still, M ...

Corning Incorporated (NYSE:GLW) is one of the stocks in focus as Jim Cramer shared his weekly game plan. Cramer noted how he spoke of the company during the latest monthly Investing Club meeting, as he said: CNBC Investing Club members, look out. You’re going to be flooded with emails Wednesday because Charitable Trust holdings, Danaher, Starbucks, GE Vernova, Microsoft, Meta, and Corning all report. Let me give you a preview… We had our investing club monthly meeting yesterday, and I spoke positively abo ...

Earnings Reports - Nucor, described as the "best steel company in the world," will report earnings on Monday, with expectations that rate cuts may spur economic growth despite a lackluster mid-quarter update in December [1] - Boeing and General Motors will release results on Tuesday, with Boeing shares having rallied significantly, leading to cautious expectations for further gains [2][3] - A busy earnings day on Wednesday will feature reports from Corning, Danaher, Starbucks, GE Vernova, Meta Platforms, and Microsoft, all of which are holdings in Cramer's Charitable Trust [4] Company Insights - Danaher is expected to have its first strong quarter in years due to a resurgence in biotech orders [6] - Starbucks is considered "wildly overbought," requiring exceptionally strong earnings to maintain upward momentum, but is still viewed positively for the long term [6] - Microsoft shares are under pressure due to AI-driven disruption risks, which are seen as a false concern [7] - GE Vernova's results are anticipated to be underwhelming due to high expectations, while Corning is favored for long-term growth due to AI-related benefits [5] Market Context - Honeywell will report on Thursday, with potential for a disappointing stock reaction as investors await the company's breakup later this year [8] - Apple is set to post results after eight weeks of decline, attributed to concerns over rising memory costs affecting margins, but the recommendation remains to "own it, don't trade it" [9] - The Federal Reserve's interest rate decision is expected to remain unchanged, with potential market-moving news regarding Fed Chair Jerome Powell's replacement [10]

Core Insights - Danaher (DHR) is expected to report quarterly earnings of $2.15 per share, reflecting a 0.5% increase year-over-year, with revenues forecasted at $6.79 billion, representing a 3.9% year-over-year increase [1] Earnings Estimates - The consensus EPS estimate has been revised upward by 0.4% in the past 30 days, indicating a reassessment by covering analysts [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3] Revenue and Sales Forecasts - Analysts predict 'Total sales- Diagnostics' to be $2.70 billion, a 2.6% increase from the previous year [5] - The average forecast for 'Total sales- Life Sciences' is $2.06 billion, indicating a 1.2% increase year-over-year [5] - 'Total sales- Biotechnology' is expected to reach $2.02 billion, reflecting a 7.9% increase from the prior-year quarter [5] Operating Profit Estimates - 'Operating profit- Life Sciences' is projected to be $258.78 million, down from $376.00 million reported in the same quarter last year [6] - 'Operating profit- Biotechnology' is expected to reach $535.78 million, compared to $508.00 million reported in the same quarter last year [6] - 'Operating profit- Diagnostics' is forecasted at $690.13 million, up from $624.00 million reported in the same quarter last year [7] Stock Performance - Over the past month, Danaher shares have returned +3.7%, outperforming the Zacks S&P 500 composite's +0.6% change [7] - Danaher currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [7]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] Investment Opportunity - A specific company is highlighted as a potential investment opportunity, possessing critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI data centers [3][7] - This company is not a chipmaker or cloud platform but is positioned to benefit significantly from the anticipated surge in electricity demand driven by AI technologies [3][6] Energy Demand and Infrastructure - AI technologies, particularly large language models like ChatGPT, are extremely energy-intensive, with data centers consuming as much energy as small cities [2] - The company in focus owns nuclear energy infrastructure, which is crucial for America's future power strategy, and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7][8] Financial Position - The company is noted for being debt-free and having a substantial cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8] - It also holds a significant equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities in the AI sector [9][10] Market Trends - The current market environment is characterized by a shift towards onshoring and increased U.S. LNG exports, driven by government policies, which the company is well-positioned to capitalize on [5][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, making investments in AI increasingly attractive [12] Conclusion - The company represents a unique investment opportunity in the intersection of AI and energy, with the potential for significant returns as the demand for energy in AI applications continues to rise [10][11][13]

Core Insights - Danaher anticipates fourth quarter 2025 results to exceed expectations, indicating strong performance in the upcoming quarter [3] - The company highlights its differentiated positions in attractive sectors such as biotechnology, life sciences, and diagnostics [3] - Danaher aims to generate sustainable long-term shareholder value through innovation, execution, capital deployment, and the Danaher Business System [3] Financial Performance - The company expects Q4 core growth to be slightly ahead of previous expectations, suggesting positive financial momentum [4]

Danaher (NYSE:DHR) FY Conference Summary Company Overview - **Company**: Danaher Corporation - **Market Capitalization**: Approximately $25 billion - **Operating Segments**: Biotechnology, Life Sciences, Diagnostics - **Financial Profile**: Gross margins nearly 60%, operating margins approaching 30%, operating cash flow over $6 billion [5][6][21] Core Financial Performance - **Q4 2025 Expectations**: Anticipated results to be ahead of expectations, with core growth towards the high end of low single-digit percentage guidance [2][3] - **2025 Adjusted EPS**: Expected to be at the high end of guidance ($7.70 to $7.80) [4] - **2026 Expectations**: Core revenue growth projected between 3% and 6%, adjusted operating profit margin expansion of over 100 basis points, and adjusted EPS growth in high single digits [4][26] Market Positioning and Growth Drivers - **End Market Strength**: Strong momentum in bioprocessing consumables (high single-digit growth) and diagnostics, particularly in respiratory markets [3][4] - **Recurring Revenue**: Approximately 80% of revenue is recurring, driven by consumables and a large installed base [7] - **Secular Growth Drivers**: - Aging global population projected to exceed 1.5 billion over 65 by 2050, increasing healthcare demand [8] - Shift towards biologics with over 20,000 biologics in the pipeline [9] - Growth in molecular diagnostics, which has expanded 2.5 times since 2019 [10] - Advancements in life sciences research driving new therapy classes [10] Segment Performance Bioprocessing - **Revenue**: Over $6 billion, with 80% from monoclonal antibodies [11] - **Growth Outlook**: High single-digit core revenue growth expected in 2026, supported by reshoring and equipment growth [12][39] Life Sciences - **Revenue**: $7.3 billion, diversified across pharma, biopharma, and genomics [13] - **Growth Outlook**: High single-digit long-term core revenue growth with margin expansion opportunities [14][43] Diagnostics - **Revenue**: $10 billion, with strong performance from Cepheid in molecular diagnostics [14] - **Growth Outlook**: Double-digit growth expected in molecular diagnostics, with mid-single-digit growth in other segments [15][48] Innovation and Product Development - **New Products**: Significant innovations such as the ZenoTOF 7600 mass spectrometer and the DxI 9000 immunoassay analyzer, enhancing drug discovery and diagnostics capabilities [16][18] - **Impact on Revenue**: New product revenue increased by 25% over the last year [19] Capital Allocation and M&A Strategy - **Focus on M&A**: Capital allocation bias towards acquisitions, with a disciplined approach based on market analysis and company positioning [21][46] - **Market Conditions**: Improved conditions for M&A with stabilized risks and more reasonable valuations [46] Challenges and Market Outlook - **Near-term Hurdles**: Ongoing normalization in the diagnostics market, particularly in China, with expectations for continued improvement [29][30] - **Long-term Confidence**: Strong conviction in the underlying health of end markets, with positive momentum expected in 2026 and beyond [27][28] Summary - Danaher is well-positioned in attractive biotechnology, life sciences, and diagnostics markets, with a strong financial profile and significant growth opportunities driven by innovation and market trends. The company anticipates continued growth and margin expansion in 2026, supported by a robust pipeline of new products and a disciplined approach to capital allocation and M&A.